Drugs / Potassium
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00823108 | Mar 2009 → Oct 2010 | infectious disease with sepsis | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05627479 | Dec 2024 → Jan 2026 | bone disorder | NYU Langone Health | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT00000501 | Sep 1981 → Aug 1986 | heart disorder, hypertensive disorder, obesity disorder | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT04053816 | Oct 2020 → Nov 2023 | cardiac rhythm disease | Barts & The London NHS Trust | Completed | Met primary |
| Phase 3 | NCT03195647 | Aug 2017 → Apr 2018 | cardiac rhythm disease | Barts & The London NHS Trust | Completed | No outcome recorded |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT01384656 | Feb 2011 → Feb 2012 | acute coronary syndrome | Yonsei University | Completed | Met primary |
| Phase not applicable2 trials · 1 missed | ||||||
| — | NCT01825720 | Mar → May 2013 | heart valve disorder | Yonsei University | Completed | Missed primary |
| — | NCT01404078 | Apr 2010 → Feb 2011 | ischemic stroke, myocardial ischemia, peripheral vascular disease, type 2 diabetes mellitus | St. John's Research Institute | Completed | No outcome recorded |
| Comparator or background therapy10 trials | ||||||
| Phase 1 | NCT00801034 Comparator | Nov 2008 → Nov 2011 | hypertensive disorder | Erling Bjerregaard Pedersen | Completed | No outcome recorded |
| Phase 1/2 | NCT01146197 Background | Feb 2010 → Dec 2012 | Gitelman syndrome | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT00282867 Comparator | May 2006 → Feb 2008 | hyperglycemia, ischemic stroke | University of Virginia | Completed | No outcome recorded |
| Phase 3 | NCT00965406 Background | Aug 2010 → Dec 2013 | acute coronary syndrome | University of Monastir | Completed | Met primary |
| Phase 4 | NCT06624956 Comparator | Sep 2024 → Sep 2025 | hyperglycemia | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT05593055 Comparator | Aug 2023 → Apr 2027 expected | hypertensive disorder | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| — | NCT07861685 Background | Oct 2026 → Mar 2027 expected | severe pre-eclampsia | Lady Reading Hospital, Pakistan | Recruiting | No outcome recorded |
| — | NCT02036372 Comparator | Jan 2014 → Jan 2017 | type 2 diabetes mellitus | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| — | NCT00899483 Comparator | Jul 2009 → Jul 2012 | type 2 diabetes mellitus | University Hospital Birmingham | Unknown | No outcome recorded |
| — | NCT00865124 Comparator | Sep 2008 → Aug 2013 | type 2 diabetes mellitus, vascular disorder | Brigham and Women's Hospital | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | potassium | “Therapy cocktail of Glucose, Insulin and Potassium. The medications will be prepared as per standard protocol. Administered intravenously.” NCT05627479 ↗17“GIK solution (potassium 80 mEq and regular insulin 325 IU in 500 ml of 50% glucose)” PMID 22986417 ↗ Sep 2012 “a supplementation with potassium and magnesium will be orally given” NCT01146197 ↗ “2 Capsules of low strength polycap with 30mEq of Potassium” NCT01404078 ↗ “GIK (glucose -insulin - potassium) infusion” NCT02036372 ↗ “Glucose-insulin-potassium” NCT00823108 ↗ “70 mEq of Potassium” NCT00965406 ↗ |
| Modality | Small molecule | — CHEMBL1201290 ↗ |
| Route | Intravenous | “IV glucose insulin and potassium, GIK” NCT00282867 ↗ |